Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to ...
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...
Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...
Also Read: Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin ...
HBM Healthcare Investments AG / Key word (s): Annual Results HBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year 01-Apr-2025 / 17:49 CET/CEST ...
In a bid to pursue growing sales, Sanofi doubled down on investing in immunology with the $600 million upfront buyout of Dren Bio’s clinical stage bispecific antibody. The antibody has been evaluated ...
South Korean biotech ABL Bio has lined up another platform license agreement with a European pharma giant in the ...
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...
In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, first signed more than a decade ago, paying an upfront fee of €50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback